Scotiabank Maintains Sector Perform on Biomarin Pharmaceutical, Lowers Price Target to $78
Portfolio Pulse from Benzinga Newsdesk
Scotiabank analyst George Farmer maintains a Sector Perform rating on Biomarin Pharmaceutical (NASDAQ:BMRN) but lowers the price target from $95 to $78.

September 17, 2024 | 3:25 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Scotiabank has maintained its Sector Perform rating on Biomarin Pharmaceutical but has lowered the price target from $95 to $78, indicating a less optimistic outlook.
The lowering of the price target from $95 to $78 by Scotiabank suggests a less optimistic view on Biomarin's future performance, which could lead to a negative short-term impact on the stock price. The maintained Sector Perform rating indicates that the stock is expected to perform in line with the sector, but the reduced price target reflects potential challenges or lower growth expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100